- PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)
-
The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.
- -
-
Page/Page column 20
(2008/12/07)
-
- Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound
-
The medicinal chemistry strategy which led to the identification of GR205171, an orally active non-peptide neurokinin-1 receptor antagonist that is the most potent broad-spectrum antiemetic agent reported to date.
- Armour,Chung,Congreve,Evans,Guntrip,Hubbard,Kay,Middlemiss,Mordaunt,Pegg,Vinader,Ward,Watson
-
p. 1015 - 1020
(2007/10/03)
-
